The stomach cancer treatment market size was valued at around USD 4.22 Bn in 2022 and is estimated to reach USD 11.96 Bn by 2031, expanding at a CAGR of 13.1% during the forecast period, 2023-2031. The growth of the market is attributed to the growing advancement of technologies for the treatment of stomach cancer.
Stomach cancer also called gastric cancer, refers to the growth of cancer cells in the stomach. Gastric cancer can affect any part of the stomach and is more likely to hit the main part called as stomach body. According to the studies, it is expected to start at the gastroesophageal junction.
Metastatic stomach cancer is a type of stomach cancer that spreads to the other part of the body. It has a slow progression and symptoms occur late, causing a delay in its diagnosis. Besides the availability of treatment for stomach cancer, the mortality rate remains high due to the widespread practice of late diagnosis.
The early symptoms of gastric cancer include slight nausea, indigestion, loss of appetite, heartburn, and others. However, when stomach cancer gets serious, symptoms such as yellowish eyes or skin, stomach pain, blood in stool, vomiting, swelling in the stomach, constipation, weight loss, and others can be observed.
There are various methods available for the treatment of stomach cancer that includes chemotherapy, surgery, targeted drugs, and others. Depending upon the stage of cancer, different types of treatment are used for treating the patients. As per the estimations by GLOBOCAN in 2018, the number of stomach cancer cases in Asia was nearly 769,728 and was anticipated to reach 947,186 by 2025.
According to Cancer Research U.K., around 6,697 cases of gastric carcinoma are diagnosed every year. To embark on the first-line treatment for stomach cancer has encouraged a large number of pharmaceutical giants to conduct research for the development of novel stomach cancer drugs.
The survival chances of a stomach cancer patient can be improved through using chemotherapy; however, the overall rate of their survival is still very low. Various studies also show that the survival rate of stomach cancer patients can be improved using molecular targeted therapy.
Covid-19 pandemic has significantly impacted the stomach cancer treatment market size. According to the National Center for Biotechnology Information (NCBI), the pandemic caused delays in the diagnosis of cancer patients and hospitals de-prioritized non covid-19 patients. For instance, In England, 60% of patients for chemotherapy were unable to get hospitalized during the initial stage of the pandemic. However, the increasing adoption of Enhertu and Opdivo products in various countries and the rising diagnosis rate are expected to drive the market.
Stomach Cancer Treatment Market Dynamics
Drivers
Increasing prevalence of gastrointestinal stromal tumors, lymphoma, carcinoid tumors, and adenocarcinoma is driving the market. Launch of novel therapies for the treatment of metastatic stomach cancer is another factor boosting the growth of the stomach cancer treatment market. Further, the rising number of centers for the treatment of cancer along with the rise in the usage of combination therapies are expected to fuel market growth in the coming years.
Restraints
High cost of cancer therapy and side effects caused by cancer drugs are anticipated to hinder the growth of the market in the forecast period. Radiation devices are complicated in nature and have to go through a strict monitoring process, which are two major challenges expected to hamper the market growth.
Opportunities
Increasing activities for research & development and innovations in the treatment of stomach cancer present key opportunities for market expansion. Stomach Cancer Drugs such as Herceptin and Cyramza are often used in the treatment of gastric cancer while keeping the standard care of chemotherapy alive. Immunotherapy drugs for the treatment are underway for approval which is expected to be the rising factor for the market growth in the projected period.
Scope of Stomach Cancer Treatment Report
The global stomach cancer treatment report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Stomach Cancer Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020 – 2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Chemotherapy, Targeted Drug Therapy [Imatinib, Trastuzumab, and Sunitinib], Surgery, Adjuvant Chemotherapy, and Radiation Therapy), Diseases Indication (Gastric Cancer and Gastrointestinal Stromal Tumor), Drug Class (PD-1 Inhibitors, HER2 Antagonists, and VEGFR2 Antagonists), Route of Administration (Oral and Injectable), and End-user (Clinics, Ambulatory Surgical Centers, Hospitals, and Cancer Treatment Centers)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Stomach Cancer Treatment Market Size and Analysis, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
F. Hoffmann-La Roche Ltd.; Eli Lilly and Co.; GlaxoSmithKline PLC.; Novartis International AG; Merck KGaA; Otsuka Holdings Co. Ltd.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Celltrion Healthcare Co., Ltd.; Samsung Bioepis; Bristol Myers Squibb Company; and Mylan N.V.
|
Stomach Cancer Treatment Market Segment Insights
On the basis of treatment type, the global stomach cancer treatment market is divided into chemotherapy, targeted drug therapy, surgery, adjuvant chemotherapy, and radiation therapy. The targeted drug therapy segment is further segmented into imatinib, trastuzumab, and sunitinib. The targeted drug therapy segment is expected to hold a high share of the market during the forecast period owing to the conveyance of techniques that are highly advanced such as immunotherapy, stem cell therapy, and enzyme therapy.
In terms of disease indication, the market is segmented into indication gastric cancer and gastrointestinal stromal tumor. The gastric cancer segment is expected to expand at a rapid pace during the projected period, owing to the launch of advanced products for this indication.
On the basis of drug class, the market is categorized as PD-1 inhibitors, HER2 antagonists, and VEGFR2 antagonists. The PD-1 inhibitors segment is anticipated to boost the market growth in the coming years, due to the increasing usage of Keytruda and Opdivo for the diagnosis of gastric cancer.
Based on the route of administration, the market is bifurcated into oral and injectable. The injectable segment is expected to dominate the stomach cancer treatment market in the forecast period, owing to the availability of a large number of stomach cancer drugs in the injectable form. For instance, chemotherapy drugs, targeted drugs, and immunotherapy drugs are available in injectable form.
On the basis of end-user, the market is classified as clinics, ambulatory surgical centers, hospitals, and cancer treatment centers. The hospital segment is anticipated to account for a key market share during the projected period attributed to the availability of advanced treatment facilities and the presence of high-skill medical staff including doctors and nurses in hospitals.
In terms of region, the global stomach cancer treatment market is divided into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Asia Pacific is estimated to grow at a rapid pace during the projected period owing to the presence of a high number of stomach cancer patients in the region. However, North America is anticipated to expand at a moderate growth rate during the projected period, due to the low rate of occurrence of stomach cancer in the region.
Segments
The global stomach cancer treatment market has been segmented on the basis of
Treatment Type
- Chemotherapy
- Targeted Drugs Therapy
- Imatinib
- Trastuzumab
- Sunitinib
- Surgery
- Adjuvant Chemotherapy
- Radiation Therapy
Diseases Indication
- Gastric Cancer
- Gastrointestinal Stromal Tumor
Drug Class
- PD-1 Inhibitors
- HER2 Antagonists
- VEGFR2 Antagonists
Route of Administration
End-user
- Clinics
- Ambulatory Surgical Centers
- Hospitals
- Cancer Treatment Centers
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- F. Hoffmann-La Roche Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline PLC.
- Novartis International AG
- Merck KGaA
- Otsuka Holdings Co. Ltd.
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- Celltrion Healthcare Co., Ltd.
- Samsung Bioepis
- Bristol Myers Squibb Company
- Mylan N.V.
Competitive Landscape
Key players in the global stomach cancer treatment market are F. Hoffmann-La Roche Ltd.; Eli Lilly and Co.; GlaxoSmithKline PLC.; Novartis International AG; Merck KGaA; Otsuka Holdings Co. Ltd.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Celltrion Healthcare Co., Ltd.; Samsung Bioepis; Bristol Myers Squibb Company; and Mylan N.V.
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
- In May 2021, Bold Therapeutics received Orphan Drug Designation (ODD) for 100 patients in the treatment of gastric cancer. BOLD-100 is a first-in-class ruthenium-based small molecule therapeutics.
- In April 2021, Bristol Myers Squibb received approval from the U.S. FDA for Opdiva (nivolumab) for first-line-treatment of stomach cancer as an immunotherapy.
- In March 2021, Amgen announced an acquisition agreement with Five Prime Therapeutics. Under the agreement anti- FGFR2b antibody for stomach cancer is added to Amgen’s oncology portfolio.
Request For Customization
Enquiry Before Buying
Speak With Analyst
